Publication:
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China.

dc.contributor.authorShen, Tao
dc.contributor.authorLiu, Yingxia
dc.contributor.authorShang, Jia
dc.contributor.authorXie, Qing
dc.contributor.authorLi, Jun
dc.contributor.authorYan, Ming
dc.contributor.authorXu, Jianming
dc.contributor.authorNiu, Junqi
dc.contributor.authorLiu, Jiajun
dc.contributor.authorWatkins, Paul B
dc.contributor.authorAithal, Guruprasad P
dc.contributor.authorAndrade, Raúl J
dc.contributor.authorDou, Xiaoguang
dc.contributor.authorYao, Lvfeng
dc.contributor.authorLv, Fangfang
dc.contributor.authorWang, Qi
dc.contributor.authorLi, Yongguo
dc.contributor.authorZhou, Xinmin
dc.contributor.authorZhang, Yuexin
dc.contributor.authorZong, Peilan
dc.contributor.authorWan, Bin
dc.contributor.authorZou, Zhengsheng
dc.contributor.authorYang, Dongliang
dc.contributor.authorNie, Yuqiang
dc.contributor.authorLi, Dongliang
dc.contributor.authorWang, Yuya
dc.contributor.authorHan, Xi'an
dc.contributor.authorZhuang, Hui
dc.contributor.authorMao, Yimin
dc.contributor.authorChen, Chengwei
dc.date.accessioned2023-01-25T10:30:40Z
dc.date.available2023-01-25T10:30:40Z
dc.date.issued2019-02-08
dc.description.abstractWe performed a nationwide, retrospective study to determine the incidence and causes of drug-induced liver injury (DILI) in mainland China. We collected data on a total of 25,927 confirmed DILI cases, hospitalized from 2012 through 2014 at 308 medical centers in mainland China. We collected demographic, medical history, treatment, laboratory, disease severity, and mortality data from all patients. Investigators at each site were asked to complete causality assessments for each case whose diagnosis at discharge was DILI (n = 29,478) according to the Roussel Uclaf Causality Assessment Method. Most cases of DILI presented with hepatocellular injury (51.39%; 95% confidence interval [CI] 50.76-52.03), followed by mixed injury (28.30%; 95% CI 27.73-28.87) and cholestatic injury (20.31%; 95% CI 19.80-20.82). The leading single classes of implicated drugs were traditional Chinese medicines or herbal and dietary supplements (26.81%) and antituberculosis medications (21.99%). Chronic DILI occurred in 13.00% of the cases and, although 44.40% of the hepatocellular DILI cases fulfilled Hy's Law criteria, only 280 cases (1.08%) progressed to hepatic failure, 2 cases underwent liver transplantation (0.01%), and 102 patients died (0.39%). Among deaths, DILI was judged to have a primary role in 72 (70.59%), a contributory role in 21 (20.59%), and no role in 9 (8.82%). Assuming the proportion of DILI in the entire hospitalized population of China was represented by that observed in the 66 centers where DILI capture was complete, we estimated the annual incidence in the general population to be 23.80 per 100,000 persons (95% CI 20.86-26.74). Only hospitalized patients were included in this analysis, so the true incidence is likely to be higher. In a retrospective study to determine the incidence and causes of DILI in mainland China, the annual incidence in the general population was estimated to be 23.80 per 100,000 persons; higher than that reported from Western countries. Traditional Chinese medicines, herbal and dietary supplements, and antituberculosis drugs were the leading causes of DILI in mainland China.
dc.identifier.doi10.1053/j.gastro.2019.02.002
dc.identifier.essn1528-0012
dc.identifier.pmid30742832
dc.identifier.unpaywallURLhttps://doi.org/10.1053/j.gastro.2019.02.002
dc.identifier.urihttp://hdl.handle.net/10668/13545
dc.issue.number8
dc.journal.titleGastroenterology
dc.journal.titleabbreviationGastroenterology
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.page.number2230-2241.e11
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAsia
dc.subjectEpidemiology
dc.subjectJaundice
dc.subjectRUCAM
dc.subject.meshAcute Disease
dc.subject.meshAdult
dc.subject.meshAge Distribution
dc.subject.meshAged
dc.subject.meshCause of Death
dc.subject.meshChemical and Drug Induced Liver Injury
dc.subject.meshChina
dc.subject.meshChronic Disease
dc.subject.meshCohort Studies
dc.subject.meshConfidence Intervals
dc.subject.meshEnd Stage Liver Disease
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIncidence
dc.subject.meshLiver Failure, Acute
dc.subject.meshLiver Function Tests
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRegistries
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Assessment
dc.subject.meshSeverity of Illness Index
dc.subject.meshSex Distribution
dc.subject.meshSurvival Rate
dc.subject.meshYoung Adult
dc.titleIncidence and Etiology of Drug-Induced Liver Injury in Mainland China.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number156
dspace.entity.typePublication

Files